Accurate Education - How Curcumin Impacts Pain Processing

Pain Processing:

How Curcumin Impacts Pain Processing

Curcumin exerts therapeutic effects across all levels of the pain processing pathway, with particularly robust actions at the spinal cord dorsal horn where it targets neuroinflammation-driven central sensitization.

See:

How Nutraceuticals Impact Pain Processing

Pain Processing

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

See (On this Page):

Curcumin: Pain Processing Effects vs. Direct Tissue-Modifying Effects

How Curcumin Impacts Pain Processing

Curcumin exerts therapeutic effects across all levels of the pain processing pathway, with particularly robust actions at the spinal cord dorsal horn where it targets neuroinflammation-driven central sensitization.

The Levels of Pain Processing can be organized as follows:

Level 1: Peripheral Nociception (Pain Receptor Transduction)
Level 2: Primary Afferent Transmission to Spinal Cord
Level 3: Spinal Cord Dorsal Horn Processing (First Synapse)
Level 4: Ascending Spinal Pathways and Supraspinal Processing
Level 5: Thalamic and Cortical Processing and Pain Perception
Level 6: Descending Pain Modulation

Level 1: Peripheral Nociception (Transduction)

At the peripheral level, curcumin reduces nociceptor sensitization through multiple mechanisms. It antagonizes TRPV1 (transient receptor potential vanilloid 1) channels, blocking capsaicin-induced currents in dorsal root ganglia neurons and reducing thermal hyperalgesia.[1][2] Curcumin inhibits phosphorylation of TRPV1 on afferent fibers projecting from both peptidergic (CGRP-positive) and non-peptidergic (IB4-positive) nociceptive neurons, thereby reducing receptor sensitization.[3] Additionally, curcumin suppresses the release of pro-nociceptive neuropeptides—substance P and calcitonin gene-related peptide (CGRP)—from primary afferent terminals, directly reducing peripheral sensitization.[4] Curcumin also attenuates thermal hyperalgesia by modulating antioxidant enzymes and downregulating TNF-α, IL-1β, and IL-6.[5]

—

Level 2: Primary Afferent Transmission

Curcumin protects primary afferent nerve fibers through its anti-inflammatory and antioxidant properties. In models of peripheral nerve injury, curcumin provided sustained anti-neuroinflammatory effects, preventing overexpression of TRPV1 in lumbar DRG neurons and reducing chemokine signaling (CCL2, CSF-1) that drives central sensitization.[6] Curcumin also reduces TNF-α-induced neuroinflammation in DRG cultures by inhibiting IL-6 and COX-2 expression through AKT and ERK pathway modulation.[7]

Level 3: Spinal Cord Dorsal Horn Processing (First Synapse)

The spinal cord dorsal horn represents curcumin’s most extensively studied site of action for pain modulation. Curcumin targets multiple mechanisms of central sensitization:

Glial Cell Modulation: Curcumin potently inhibits activation of both microglia and astrocytes in the spinal cord. It reduces expression of microglial markers (IBA-1, CD11b) and astrocyte markers (GFAP), and critically, promotes microglial phenotype switching from pro-inflammatory M1 to anti-inflammatory M2.[8][9] This shift decreases release of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) while increasing anti-inflammatory cytokines (IL-10, TGF-β).[10]
Inflammasome Suppression: Curcumin inhibits both NLRP3 and NALP1 inflammasome activation in spinal cord glia.[11][12] It suppresses NLRP3 inflammasome components (NLRP3, ASC, caspase-1) and downstream IL-1β and IL-18 production through induction of autophagy.[11] In astrocytes specifically, curcumin inhibits NALP1 inflammasome aggregation and JAK2-STAT3 signaling, reducing mature IL-1β production.[12]

—

Level 5: Thalamic and Cortical Processing

Curcumin crosses the blood-brain barrier and exerts direct effects on supraspinal pain processing centers. In the amygdala—a key structure for the emotional-affective dimension of pain—curcumin reduces microglial activation (IBA-1), oxidative stress (TLR4), and mitochondrial dysfunction markers (PGC1α).[6]

Curcumin also modulates brain monoamine neurotransmitters critical to pain perception and mood:[13][14]

1. Serotonin (5-HT): Increases serotonin levels in cortex and limbic regions; upregulates tryptophan hydroxylase-2 and 5-HT receptors; inhibits MAO-A
2. Dopamine: Increases dopamine levels at higher doses; inhibits MAO-B
3. Norepinephrine: Modulates noradrenergic transmission

Level 6: Descending Pain Modulation

Curcumin’s enhancement of serotonergic neurotransmission directly supports descending inhibitory pathways. Studies demonstrate that curcumin’s antidepressant and analgesic effects in neuropathic pain models are mediated through the supraspinal serotonergic system—intracerebroventricular (but not intrathecal) administration of serotonin receptor antagonists blocked curcumin’s antidepressant effects, while intrathecal administration blocked analgesic effects, suggesting pharmacologically separable actions at different levels.[15] Chemical depletion of brain serotonin abolished curcumin’s behavioral effects, confirming dependence on intact descending monoaminergic systems.[16]

—

Clinical Evidence Supporting Pain Pathway Effects

Clinical trials support curcumin’s multi-level analgesic effects. In osteoarthritis, a 2024 umbrella meta-analysis of 11 meta-analyses confirmed significant improvements in VAS pain scores and WOMAC function/stiffness scores (all p≤0.001), with effects comparable to NSAIDs but with fewer adverse events.[17][18] The VA/DoD Clinical Practice Guidelines note that curcumin (particularly bioavailability-enhanced formulations like BCM-95) produces positive effects on pain and function at 1-3 months, with significant reductions in withdrawals due to adverse events compared to ibuprofen or diclofenac.[19]

Integration with the 4 Pathological Processes

Pathological Process	Curcumin Mechanism	Pain Pathway Impact	Corrected References
Systemic Inflammation	Inhibits NF-κB activation; suppresses COX-2, iNOS, TNF-α, IL-1β, IL-6; reduces MCP-1 and macrophage migration; modulates JAK/STAT and MAPK/ERK pathways	Decreases peripheral sensitization; reduces inflammatory mediator-induced nociceptor activation	Aggarwal BB, Sung B. Trends Pharmacol Sci. 2009;30(2):85-94[1]; Liu M et al. Front Pharmacol. 2025;16:1642248[2]; Gong X et al. PLoS One. 2025;20(10):e0335139[3]
Neuroinflammation	Suppresses microglial and astrocyte activation; promotes M1→M2 microglial polarization; inhibits NLRP3/NALP1 inflammasomes; reduces spinal IL-1β, IL-18; decreases TLR4 signaling	Prevents/reverses central sensitization; reduces glial-mediated synaptic facilitation	Zhou B, Hu B. Front Pharmacol. 2025;16:1658115[4]; Zhang J et al. Mol Immunol. 2019;116:29-37[5]; Qiao P et al. Curr Alzheimer Res. 2020;17(8):735-752[6]
Oxidative Stress	Activates Nrf2/ARE pathway; increases SOD, catalase, glutathione peroxidase; reduces MDA, protein carbonyls, ROS; scavenges free radicals; activates SIRT1	Protects DRG neurons, spinal neurons, and supraspinal structures from oxidative damage	Lin X et al. PLoS One. 2019;14(5):e0216711[7]; Park JY et al. Sci Rep. 2021;11(1):8430[8]; Shin JW et al. Biochem Pharmacol. 2020;173:113820[9]
Mitochondrial Dysfunction	Increases Complex I expression; regulates mitochondrial calcium homeostasis; prevents calcium overload and mitochondrial swelling; modulates PINK1; improves mitochondrial biogenesis via cAMP/PKA/AMPK pathway	Restores neuronal bioenergetics; prevents excitotoxicity; supports synaptic function in spinal cord and brain	Hamidie RDR et al. Br J Nutr. 2021;126(11):1642-1650[10]; Sathyabhama M et al. Biomolecules. 2022;12(10):1405[11]; Yu T et al. J Cell Physiol. 2019;234(5):6371-6381[12]

—

Detailed Mechanisms:

Systemic Inflammation

Curcumin mediates its anti-inflammatory effects through downregulation of inflammatory transcription factors (NF-κB), enzymes (COX-2 and 5-lipoxygenase), and cytokines (TNF-α, IL-1β, IL-6).[1][2] Network pharmacology analysis identified 135 potential targets for curcumin’s anti-inflammatory effects, with key pathways including TNF, HIF-1, PI3K-Akt, JAK-STAT, and MAPK signaling.[3] Importantly, curcumin’s anti-inflammatory activity is mediated by its oxidative metabolites—synthetic curcumin analogs that undergo oxidative transformation potently inhibit NF-κB, whereas stable, non-oxidizable analogs are less active.[13] Curcumin mediates its apoptotic and anti-inflammatory activities through modulation of the redox status of the cell, with glutathione reversing curcumin’s inhibition of TNF-mediated NF-κB activation.[14]

Neuroinflammation

Within neuroinflammatory pathologies, microglial cells are the primary site of curcumin’s biological activity in the CNS.[4] Curcumin demonstrates multimodal regulatory effects including modulation of key signaling pathways (NF-κB, NLRP3 inflammasome, and Nrf2) and upregulation of anti-inflammatory cytokines (TGF-β and IL-10).[4] Longvida Optimised Curcumin (500 ppm for 6 months) led to a significant reduction in Iba-1 microglia by 26% in the hippocampus and 48% in the cerebellum, and GFAP astrocytes by 30%.[15] Curcumin switches the M1 pro-inflammatory phenotype to the M2 anti-inflammatory phenotype by decreasing expression of M1 markers (iNOS, IL-1β, IL-6, CD16/32) and elevating M2 markers (arginase 1, IL-4, IL-10, CD206) via TREM2/TLR4/NF-κB pathways.[5] This M2 polarization is mediated through CaMKKβ-dependent activation of the AMPK signaling pathway.[6]

—

Oxidative Stress

Curcumin resists oxidants by increasing the activity of antioxidant enzymes (CAT, SOD, GSH-PX) and activating the Nrf2-Keap1 pathway.[7] Curcumin activates Nrf2 through PKCδ-mediated p62 phosphorylation at Ser351, with p62 knockout abolishing curcumin-induced Nrf2 activation.[8] The α,β-unsaturated carbonyl moiety of curcumin is essential for its binding to Keap1 Cys151, which facilitates liberation of Nrf2 by hampering ubiquitination and proteasomal degradation.[9] Curcumin also upregulates the Nrf2 system by repressing inflammatory signaling-mediated Keap1 expression—TNF-α stimulates Keap1 synthesis and increases Nrf2 polyubiquitination, effects significantly inhibited by curcumin.[17]

—

Mitochondrial Dysfunction

Curcumin induces mitochondrial biogenesis by increasing cAMP levels via phosphodiesterase 4A (PDE4A) inhibition, which activates the cAMP/PKA/AMPK signaling pathway and increases PGC-1α deacetylation.[10] Curcumin’s effects on mitochondria are concentration-dependent: low concentrations (1-5 μM) induce mild ROS increases that trigger protective mitochondrial biogenesis, while high concentrations (10-50 μM) cause sustained ROS increases leading to mPTP opening and apoptosis.[12] At low concentrations, curcumin acts as a mild mitochondrial uncoupler, which may underlie its activation of AMPK and downstream mTOR/STAT-3 signaling.[19] Curcumin also regulates mitochondrial calcium homeostasis and prevents calcium overload-induced mitochondrial swelling.[20][11]

—

Clinical Evidence Supporting Pain Pathway Effects

Clinical trials support curcumin’s multi-level analgesic effects. In osteoarthritis, meta-analyses confirm significant improvements in VAS pain scores and WOMAC function/stiffness scores, with effects comparable to NSAIDs but with fewer adverse events.[21][22][23][24]

The VA/DoD Clinical Practice Guidelines note that curcumin (particularly bioavailability-enhanced formulations like BCM-95, which has 6.93-fold greater bioavailability than normal curcumin) produces positive effects on pain and function at 1-3 months.[21] Compared to NSAIDs, evidence from multiple RCTs found no significant between-group difference for pain reduction, function, or quality of life at 4-6 weeks follow-up, but there was a significant reduction in withdrawals due to adverse events favoring curcumin over both ibuprofen and diclofenac.[21]
A 2022 systematic review (14 studies, 1,533 patients) confirmed that curcuminoid formulations were comparative to NSAIDs in reducing VAS, total WOMAC score, and WOMAC subscores for pain/stiffness/physical function.[22] Curcuminoid formulations combined with NSAIDs significantly reduced VAS and WOMAC pain scores more than NSAIDs alone.[22] Another meta-analysis (15 RCTs, 1,670 patients) found curcumin significantly more effective than placebo for VAS pain (WMD: -1.77), WOMAC total score (WMD: -7.06), and all WOMAC subscores, and not inferior to NSAIDs in pain and function outcomes.[23]

Comparison with ALC: Complementary Mechanisms

While both ALC and curcumin address all four pathological processes and act at multiple pain pathway levels, their primary mechanisms differ substantially, making them potentially complementary in combination therapy:

ALC: Epigenetic upregulation of mGlu2 receptors (inhibiting glutamate release); acetyl group donor for neurotransmitter synthesis; direct mitochondrial support via fatty acid transport
Curcumin: Epigenetic downregulation of pro-nociceptive genes via HAT inhibition; TRPV1 antagonism; inflammasome suppression; microglial phenotype switching

These complementary mechanisms suggest potential synergy when used together in the nutraceutical paradigm:

Feature	Curcumin	Acetyl-L-Carnitine (ALC)	References
Primary Mechanism	Multi-target anti-inflammatory (NF-κB, COX-2, cytokines); receptor modulation (TRPV1, opioid, cannabinoid)	Epigenetic upregulation of mGlu2 receptors; acetyl group donor for histone acetylation	[1], [2]
Onset of Action	Relatively rapid (days to weeks); acute receptor effects	Delayed (weeks to months); requires gene transcription changes	[1]
Duration of Effect	Requires continuous administration	Outlasts treatment duration—analgesia persists 14-37 days after drug withdrawal due to epigenetic modifications	[1]
Primary Pain Pathway Level	Peripheral nociception (TRPV1) + Spinal cord (glial modulation)	Spinal cord dorsal horn (mGlu2 upregulation) + DRG (nerve regeneration)	[1], [2]
Nerve Regeneration	Indirect (via anti-inflammatory/antioxidant protection)	Direct neurotrophic effects—enhances NGF responsiveness, promotes axonal transport, increases nerve fiber density	[2], [3], [4]
Epigenetic Mechanism	Modulates histone acetylation indirectly via SIRT1 activation	Direct acetyl group donation to NF-κB p65/RelA → enhanced GRM2 gene transcription → mGlu2 receptor upregulation	[1], [2], [5]
Glutamate Modulation	Indirect (via glial suppression reducing glutamate release)	Direct—mGlu2 receptor upregulation inhibits presynaptic glutamate release at spinal synapses	[1], [6]
Neurotransmitter Effects	Serotonin, dopamine, norepinephrine modulation (supraspinal)	Acetylcholine synthesis (cholinergic effect); serotonin and dopamine modulation	[1], [7], [8]
Clinical Evidence Strength	Strong (multiple meta-analyses in OA; comparable to NSAIDs)	Moderate (meta-analysis shows VAS reduction; dose-dependent effects >1500 mg/day)	[9], [10], [11], [12]
Best Clinical Application	Inflammatory pain (OA, RA); tissue-related pain with inflammation	Neuropathic pain (diabetic, HIV, CIPN); nerve regeneration; nociplastic pain (fibromyalgia)	[1], [2], [11]

—

Mechanistic Complementarity:

Rationale for Combination of Acetyl-L-Carnitine (ALC) with Curcumin

The combination of curcumin and ALC offers synergistic potential through non-overlapping mechanisms:

1. Temporal Complementarity: Curcumin provides rapid-onset analgesia through acute receptor modulation (TRPV1 antagonism, opioid/cannabinoid activation), while ALC provides delayed but long-lasting analgesia through epigenetic mGlu2 upregulation that persists after treatment cessation.[1]

2. Spatial Complementarity: Curcumin acts predominantly at peripheral nociceptors (TRPV1) and spinal glia (microglia/astrocyte suppression), while ALC acts primarily at spinal nerve terminals (mGlu2 receptors) and DRG neurons (nerve regeneration).[1][2]

3. Glutamate Pathway Convergence: Both reduce spinal glutamatergic transmission but through different mechanisms—curcumin by suppressing glial glutamate release, ALC by upregulating inhibitory mGlu2 autoreceptors that reduce presynaptic glutamate release.[1][6]

4. Mitochondrial Support: Both support mitochondrial function—curcumin through biogenesis induction (cAMP/PKA/AMPK pathway) and ALC through its essential role in fatty acid β-oxidation and energy metabolism.[13][7][8]

5. Neuroinflammation: Curcumin provides acute suppression of microglial/astrocyte activation, while ALC provides sustained neuroprotection through neurotrophic effects and enhanced NGF responsiveness.[14][2][3]

—

Comparison with Other Nutraceuticals: Complementary Mechanisms

Nutraceutical	Primary Mechanism	Complementarity with Curcumin	Complementarity with ALC	References
PEA	Endocannabinoid modulation (PPAR-α, CB2 indirect); mast cell stabilization	Additive: PEA targets endocannabinoid system while curcumin targets opioid/cannabinoid receptors directly	Additive: PEA + ALC combination (um-PEA/LAC 1:1) shows superior anti-inflammatory/anti-nociceptive effects vs. separate administration	[1]
Alpha-Lipoic Acid (ALA)	Antioxidant; mitochondrial cofactor; TRPA1 modulation	Complementary antioxidant pathways (ALA regenerates glutathione; curcumin activates Nrf2)	Complementary neuroprotection: ALA provides acute antioxidant protection; ALC provides nerve regeneration	[2]
Omega-3 Fatty Acids	SPM generation; membrane fluidity; anti-inflammatory	Synergistic: Omega-3 generates SPMs for resolution; curcumin suppresses initiation of inflammation	Complementary: Omega-3 supports membrane function; ALC supports mitochondrial fatty acid metabolism	[2]
Magnesium	NMDA receptor antagonism; muscle relaxation	Complementary: Curcumin targets peripheral/glial mechanisms; magnesium targets central NMDA-mediated sensitization	Complementary: Both reduce glutamatergic transmission through different mechanisms (NMDA block vs. mGlu2 upregulation)	[2]
Melatonin	MT2 receptor → endogenous opioid recruitment; antioxidant	Synergistic opioid pathway activation: Curcumin activates peripheral opioid receptors; melatonin recruits central endogenous opioids	Complementary: Both modulate serotonergic systems; melatonin provides acute effects, ALC provides sustained effects	[2]
B Vitamins	Nerve function; neurotransmitter synthesis; homocysteine reduction	Additive: B vitamins support nerve function; curcumin provides anti-inflammatory protection	Synergistic: Both support nerve regeneration and function through different mechanisms	[2]
Boswellia	5-LOX inhibition (oral); TRPV1/TRPA1 modulation (topical)	Complementary: Curcumin inhibits COX-2; Boswellia inhibits 5-LOX—dual eicosanoid pathway blockade	Complementary: Boswellia provides acute anti-inflammatory effects; ALC provides long-term nerve protection	[2]

—

Evidence for Specific Combinations

PEA + ALC Combination: A preclinical study demonstrated that a 1:1 mixture of ultra-micronized PEA (um-PEA) and ALC (5 mg/kg oral) produced significantly greater anti-inflammatory and anti-nociceptive effects than the same compounds administered separately but consecutively in a carrageenan-induced paw edema model. The combination reduced edema, thermal hyperalgesia, inflammatory cell infiltration, and myeloperoxidase activity more effectively than individual components.[15]

Curcumin + ALC Theoretical Synergy: No direct clinical trials compare curcumin and ALC combination therapy. However, based on their complementary mechanisms:
1. Curcumin’s rapid-onset, multi-target anti-inflammatory effects could provide immediate symptom relief
2. ALC’s epigenetic mGlu2 upregulation could provide sustained, treatment-outlasting analgesia
3. Both address the four pathological processes (inflammation, neuroinflammation, oxidative stress, mitochondrial dysfunction) through different pathways

Multi-Nutraceutical Combinations: A comprehensive review identified that combinations of nutraceuticals with conventional analgesics can extend duration of effect and lower required doses.[16] Effective combinations include:
1. B vitamins + gabapentin for neuropathic pain
2. B vitamins + diclofenac for low back pain
3. ALA for burning mouth syndrome (alone or in combination)

Curcumin: Pain Processing Effects vs. Direct Tissue-Modifying Effects

Curcumin helps with pain on how pain is processed by the nervous system and it’s impact on the pathological processes that magnify pain processing. But it also helps with pain due to direct affects modifying tissues, particularly in the case of arthritis. These two faceets are well balanced with curcumin..

Pain Processing Effects:

Curcumin demonstrates robust central pain-processing effects. Intrathecal curcumin attenuates mechanical allodynia and thermal hyperalgesia by inhibiting spinal glial activation (microglia and astrocytes) and reducing inflammatory mediators (IL-1β, MCP-1, MIP-1α) in the spinal cord—without affecting peripheral joint edema.[8] This dissociation highlights curcumin’s direct CNS analgesic action independent of peripheral tissue effects. Curcumin modulates multiple pain pathways including TRPV1 channels, mGlu2 receptors, CaMKIIα, JAK2/STAT3, JNK/MAPK, and the opioid system.[9] A 2025 meta-analysis of 59 studies confirmed curcumin’s analgesic efficacy, with oral and intraperitoneal routes showing significant pain reduction (SMD = 1.27-1.48).[10]

Direct Tissue-Modifying Effects:

Curcumin exerts direct chondroprotective effects through multiple mechanisms: it inhibits ferroptosis via SIRT5-mediated desuccinylation of ACSL4; promotes AMPK/PINK1/Parkin-mediated mitophagy to maintain mitochondrial homeostasis; suppresses NF-κB while upregulating Sox9 to restore cartilage matrix synthesis; and increases type II collagen and aggrecan expression while decreasing MMP-13 and ADAMTS5.[11][12][13][14][15] In vivo, curcumin alleviates cartilage destruction, bone erosion, and smooths subchondral bone surfaces.[11] An umbrella meta-analysis of 11 meta-analyses confirmed curcumin significantly improves WOMAC pain, function, and stiffness scores in OA.[16] In rheumatoid arthritis, curcumin reduces DAS-28, ESR, CRP, and rheumatoid factor.[17][18]

Summary:

Pain Processing vs. Tissue Modification

Mechanism	Pain Processing	Tissue Modification	References
Spinal glial inhibition (↓GFAP, ↓Iba-1)	Reduces central sensitization	None	[1]
NF-κB/Sox9 axis modulation	Reduces neuroinflammation	Restores cartilage matrix synthesis (↑collagen II, ↑CSPG)	[2]
AMPK/PINK1/Parkin mitophagy	Protects spinal neurons	Maintains chondrocyte mitochondrial homeostasis	[3]
MMP-9/ADAMTS5 inhibition	Indirect	Direct ECM preservation	[4]
SIRT5/ACSL4 ferroptosis inhibition	None	Direct chondrocyte protection	[5]
PAR-2 pathway suppression	Reduces inflammatory pain signaling	Decreases RANKL/RANK-mediated bone resorption	[6]

Clinical Evidence Summary:

A 2022 meta-analysis of 29 RCTs (2,396 participants) across five arthritis types (OA, RA, ankylosing spondylitis, juvenile idiopathic arthritis, gout) found curcumin improved inflammation and pain levels with good safety.[7] An umbrella meta-analysis confirmed significant improvements in WOMAC pain, function, and stiffness in OA.[8] In RA, curcumin reduces DAS-28, ESR, CRP, and rheumatoid factor.[9][10] Curcumin demonstrates balanced dual effects—robust pain-processing modulation through spinal glial inhibition combined with direct chondroprotection via multiple molecular targets.

Summary: Curcumin vs Acetyl-L-carnitine (ALC) vs Alpha-lipoic acid (ALA)

The evidence reveals distinct mechanistic profiles for different nutraceuticals:

Acetyl-L-carnitine (ALC) demonstrates the strongest evidence for epigenetic pain-processing effects with emerging tissue-modifying potential;
Curcumin shows balanced dual effects on both pain pathways and tissue protection; omega-3 fatty acids provide moderate pain-processing benefits with limited structural effects; and
Alpha-lipoic acid (ALA) acts primarily through antioxidant-mediated symptom relief with minimal disease-modifying evidence.:

REFERENCES (Pain Processing)

Level 1: Peripheral Nociception (TRPV1 Modulation)

1. Yeon KY, Kim SA, Kim YH, et al. Curcumin produces an antihyperalgesic effect via antagonism of TRPV1. J Dent Res. 2010;89(2):170-174. PMID: 20040737

2. Zhi L, Dong L, Kong D, et al. Curcumin acts via transient receptor potential vanilloid-1 receptors to inhibit gut nociception and reverses visceral hyperalgesia. Neurogastroenterol Motil. 2013;25(6):e429-440. PMID: 23638900

3. Yang M, Wang J, Yang C, et al. Oral administration of curcumin attenuates visceral hyperalgesia through inhibiting phosphorylation of TRPV1 in rat model of ulcerative colitis. Mol Pain. 2017;13:1744806917726416. PMID: 28812431

4. Lee JY, Shin TJ, Choi JM, et al. Antinociceptive curcuminoid, KMS4034, effects on inflammatory and neuropathic pain likely via modulating TRPV1 in mice. Br J Anaesth. 2013;111(4):667-672. PMID: 23719767

5. Singh AK, Vinayak M. Curcumin attenuates CFA induced thermal hyperalgesia by modulation of antioxidant enzymes and down regulation of TNF-α, IL-1β and IL-6. Neurochem Res. 2015;40(3):463-472. PMID: 25479948

—

Level 2: Primary Afferent Neurons/DRG

6. Santos JM, Mendes-Silva W, Afonso J, et al. Turmeric bioactive compounds alleviate spinal nerve ligation-induced neuropathic pain by suppressing glial activation and oxidative stress. Nutrients. 2023;15(20):4403. PMID: 37892476

7. Uddin SJ, Hasan MF, Afroz M, et al. Curcumin and its multi-target function against pain and inflammation: an update of pre-clinical data. Curr Drug Targets. 2021;22(6):656-671. PMID: 32981501

—

Level 3: Spinal Cord Dorsal Horn

8. Huang CT, Chen SH, Lin SC, et al. Curcumin promotes connexin 43 degradation and alleviates neuropathic pain through microglial M2 polarization in chronic constriction injury mice. Nutrition. 2023;109:112004. PMID: 36931068

9. Zhou T, Zhu Y, Sun L, et al. Curcumin suppresses NLRP3 inflammasome activation via autophagy in spinal cord injury-induced neuropathic pain. Mol Biol Rep. 2025;52(1):859. PMID: Not yet indexed

10. Liu S, Li Q, Zhang MT, et al. Curcumin ameliorates neuropathic pain by down-regulating spinal IL-1β via suppressing NALP1 inflammasome and JAK2-STAT3 signalling. Sci Rep. 2016;6:28956. PMID: 27381056

11. Chen JJ, Dai L, Zhao LX, et al. Intrathecal curcumin attenuates pain hypersensitivity and decreases spinal neuroinflammation in rat model of monoarthritis. Sci Rep. 2015;5:10278. PMID: 25988362

12. Yin H, Guo Q, Li X, et al. Curcumin suppresses IL-1β secretion and prevents inflammation through inhibition of the NLRP3 inflammasome. J Immunol. 2018;200(8):2835-2846. PMID: 29549176

—

Level 5: Thalamic/Cortical Processing

13. Zhang Y, Li L, Zhang J. Curcumin in antidepressant treatments: an overview of potential mechanisms, pre-clinical/clinical trials and ongoing challenges. Basic Clin Pharmacol Toxicol. 2020;127(4):243-253. PMID: 32544307

14. Abd-Rabo MM, Georgy GS, Saied NM, et al. Involvement of the serotonergic system and neuroplasticity in the antidepressant effect of curcumin in ovariectomized rats: comparison with oestradiol and fluoxetine. Phytother Res. 2019;33(2):387-396. PMID: 30575146

—

Level 6: Descending Pain Modulation

15. Zhao X, Wang C, Zhang JF, et al. Chronic curcumin treatment normalizes depression-like behaviors in mice with mononeuropathy: involvement of supraspinal serotonergic system and GABAA receptor. Neuropharmacology. 2012;62(2):843-854. PMID: 21945716

16. Zhao X, Xu Y, Zhao Q, et al. Curcumin exerts antinociceptive effects in a mouse model of neuropathic pain: descending monoamine system and opioid receptors are differentially involved. Psychopharmacology. 2014;231(10):2171-2187. PMID: 24297305

—

Clinical Evidence

17. Bideshki MV, Sedaghat M, Karimi E, et al. Efficacy of curcumin/turmeric for the treatment of symptoms and biomarkers of osteoarthritis: a meta-analysis of meta-analyses. Phytother Res. 2024;38(6):2875-2891. PMID: 38576215

18. Feng J, Li Z, Tian L, et al. Efficacy and safety of curcuminoids alone in alleviating pain and dysfunction for knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. BMC Complement Med Ther. 2022;22(1):276. PMID: 36261810

19. VA/DoD Clinical Practice Guideline for the Non-Surgical Management of Hip and Knee Osteoarthritis. Version 2.0. 2020. [Guideline]

20. Wan Y, Sun W, Yang J, et al. The comparison of curcuminoid formulations or its combination with conventional therapies versus conventional therapies alone for knee osteoarthritis. Clin Rheumatol. 2022;41(7):2153-2169. PMID: 35294665

21. Hsiao AF, Lien YC, Tzeng IS, et al. The efficacy of high- and low-dose curcumin in knee osteoarthritis: a systematic review and meta-analysis. Complement Ther Med. 2021;63:102775. PMID: 34537344

22. Zeng L, Yu G, Hao W, et al. The efficacy and safety of Curcuma longa extract and curcumin supplements on osteoarthritis: a systematic review and meta-analysis. Biosci Rep. 2021;41(6):BSR20210817. PMID: 34017975

—

Systemic Inflammation (NF-κB, COX-2, Cytokines)

23. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009;30(2):85-94. PMID: 19110321

24. Liu M, Wang J, Song Z, et al. Regulation mechanism of curcumin mediated inflammatory pathway and its clinical application: a review. Front Pharmacol. 2025;16:1642248. PMID: 40909997

25. Gong X, Xue D, Meng H, et al. Curcumin attenuates LPS-induced inflammation in RAW 264.7 cells: a multifaceted study integrating network pharmacology, molecular docking, molecular dynamics simulation, and experimental validation. PLoS One. 2025;20(10):e0335139. PMID: 41129534

26. Edwards RL, Luis PB, Varuzza PV, et al. The anti-inflammatory activity of curcumin is mediated by its oxidative metabolites. J Biol Chem. 2017;292(52):21243-21252. PMID: 29097552

27. Sandur SK, Ichikawa H, Pandey MK, et al. Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radic Biol Med. 2007;43(4):568-580. PMID: 17640567

—

Neuroinflammation (Microglia/Astrocyte Modulation)

28. Zhou B, Hu B. Anti-inflammatory effect of curcumin on neurological disorders: a narrative review. Front Pharmacol. 2025;16:1658115. PMID: 41132526

29. Zhang J, Zheng Y, Luo Y, et al. Curcumin inhibits LPS-induced neuroinflammation by promoting microglial M2 polarization via TREM2/TLR4/NF-κB pathways in BV2 cells. Mol Immunol. 2019;116:29-37. PMID: 31590042

30. Qiao P, Ma J, Wang Y, et al. Curcumin prevents neuroinflammation by inducing microglia to transform into the M2-phenotype via CaMKKβ-dependent activation of the AMP-activated protein kinase signal pathway. Curr Alzheimer Res. 2020;17(8):735-752. PMID: 33176649

31. Ullah F, Asgarov R, Venigalla M, et al. Effects of a solid lipid curcumin particle formulation on chronic activation of microglia and astroglia in the GFAP-IL6 mouse model. Sci Rep. 2020;10(1):2365. PMID: 32047191

32. Seady M, Fróes FT, Gonçalves CA, et al. Curcumin modulates astrocyte function under basal and inflammatory conditions. Brain Res. 2023;1818:148519. PMID: 37562565

—

Oxidative Stress (Nrf2/Keap1 Pathway)

33. Lin X, Bai D, Wei Z, et al. Curcumin attenuates oxidative stress in RAW264.7 cells by increasing the activity of antioxidant enzymes and activating the Nrf2-Keap1 pathway. PLoS One. 2019;14(5):e0216711. PMID: 31112588

34. Park JY, Sohn HY, Koh YH, et al. Curcumin activates Nrf2 through PKCδ-mediated p62 phosphorylation at Ser351. Sci Rep. 2021;11(1):8430. PMID: 33875681

35. Ren L, Zhan P, Wang Q, et al. Curcumin upregulates the Nrf2 system by repressing inflammatory signaling-mediated Keap1 expression in insulin-resistant conditions. Biochem Biophys Res Commun. 2019;514(3):691-698. PMID: 31078267

36. Shahcheraghi SH, Salemi F, Peirovi N, et al. Nrf2 regulation by curcumin: molecular aspects for therapeutic prospects. Molecules. 2021;27(1):167. PMID: 35011412

37. Shin JW, Chun KS, Kim DH, et al. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification. Biochem Pharmacol. 2020;173:113820. PMID: 31972171

—

Mitochondrial Dysfunction

38. Hamidie RDR, Shibaguchi T, Yamada T, et al. Curcumin induces mitochondrial biogenesis by increasing cyclic AMP levels via phosphodiesterase 4A inhibition in skeletal muscle. Br J Nutr. 2021;126(11):1642-1650. PMID: 33551001

39. Sathyabhama M, Priya Dharshini LC, Karthikeyan A, et al. The credible role of curcumin in oxidative stress-mediated mitochondrial dysfunction in mammals. Biomolecules. 2022;12(10):1405. PMID: 36291614

40. Yu T, Dohl J, Elenberg F, et al. Curcumin induces concentration-dependent alterations in mitochondrial function through ROS in C2C12 mouse myoblasts. J Cell Physiol. 2019;234(5):6371-6381. PMID: 30246249

41. Lim HW, Lim HY, Wong KP. Uncoupling of oxidative phosphorylation by curcumin: implication of its cellular mechanism of action. Biochem Biophys Res Commun. 2009;389(1):187-192. PMID: 19715674

42. Fedotcheva TA, Beloborodova NV, Fedotcheva NI. Common mitochondrial targets of curcumin and cinnamic acid, the membrane-active natural phenolic compounds. Pharmaceutics. 2024;16(10):1272. PMID: 39458604

—

Comparison with ALC: Complementary Mechanisms

43. Sarzi-Puttini P, Giorgi V, Di Lascio S, et al. Acetyl-L-carnitine in chronic pain: a narrative review. Pharmacol Res. 2021;173:105874. PMID: 34500063

44. Onofrj M, Ciccocioppo F, Varanese S, et al. Acetyl-L-carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond. Expert Rev Neurother. 2013;13(8):925-936. PMID: 23965166

45. Sergi G, Pizzato S, Piovesan F, et al. Effects of acetyl-L-carnitine in diabetic neuropathy and other geriatric disorders. Aging Clin Exp Res. 2018;30(2):133-138. PMID: 28534301

46. Pourshahidi S, Shamshiri AR, Derakhshan S, et al. The effect of acetyl-L-carnitine (ALCAR) on peripheral nerve regeneration in animal models: a systematic review. Neurochem Res. 2023;48(8):2335-2344. PMID: 37037995

47. Notartomaso S, Mascio G, Bernabucci M, et al. Analgesia induced by the epigenetic drug, L-acetylcarnitine, outlasts the end of treatment in mouse models of chronic inflammatory and neuropathic pain. Mol Pain. 2017;13:1744806917697009. PMID: 28326943

48. Di Cesare Mannelli L, Ghelardini C, Toscano A, et al. The neuropathy-protective agent acetyl-L-carnitine activates protein kinase C-gamma and MAPKs in a rat model of neuropathic pain. Neuroscience. 2010;165(4):1345-1352. PMID: 19925851

49. Traina G. The neurobiology of acetyl-L-carnitine. Front Biosci (Landmark Ed). 2016;21(7):1314-

50. Freo U, Brugnatelli V, Turco F, et al. Analgesic Effects of Acetyl-L-Carnitine and Ketamine. Front Neurosci. 2021;15:584649

REFEERENCES (Pain Processing Effects vs. Direct Tissue-Modifying Effects)

Acetyl-L-Carnitine in Chronic Pain: A Narrative Review. Sarzi-Puttini P, Giorgi V, Di Lascio S, Fornasari D. Pharmacological Research. 2021;173:105874. doi:10.1016/j.phrs.2021.105874.
Analgesia Induced by the Epigenetic Drug, L-Acetylcarnitine, Outlasts the End of Treatment in Mouse Models of Chronic Inflammatory and Neuropathic Pain. Notartomaso S, Mascio G, Bernabucci M, et al. Molecular Pain. 2017;13:1744806917697009. doi:10.1177/1744806917697009.
Acetyl-L-Carnitine Increases Nerve Regeneration and Target Organ Reinnervation – A Morphological Study. Wilson AD, Hart A, Wiberg M, Terenghi G. Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS. 2010;63(7):1186-95. doi:10.1016/j.bjps.2009.05.039.
The Effect of Acetyl-L-Carnitine (ALCAR) on Peripheral Nerve Regeneration in Animal Models: A Systematic Review. Pourshahidi S, Shamshiri AR, Derakhshan S, Mohammadi S, Ghorbani M. Neurochemical Research. 2023;48(8):2335-2344. doi:10.1007/s11064-023-03911-1.
Prophylactic Role of Acetyl-L-Carnitine on Knee Lesions and Associated Pain in a Rat Model of Osteoarthritis. Bianchi E, Di Cesare Mannelli L, Menicacci C, et al. Life Sciences. 2014;106(1-2):32-9. doi:10.1016/j.lfs.2014.04.022.
The Neuropathy-Protective Agent Acetyl-L-Carnitine Activates Protein Kinase C-Gamma and MAPKs in a Rat Model of Neuropathic Pain. Di Cesare Mannelli L, Ghelardini C, Toscano A, Pacini A, Bartolini A. Neuroscience. 2010;165(4):1345-52. doi:10.1016/j.neuroscience.2009.11.021.
Effects of Acetyl-L-Carnitine in Diabetic Neuropathy and Other Geriatric Disorders. Sergi G, Pizzato S, Piovesan F, et al. Aging Clinical and Experimental Research. 2018;30(2):133-138. doi:10.1007/s40520-017-0770-3.
Intrathecal Curcumin Attenuates Pain Hypersensitivity and Decreases Spinal Neuroinflammation in Rat Model of Monoarthritis. Chen JJ, Dai L, Zhao LX, et al. Scientific Reports. 2015;5:10278. doi:10.1038/srep10278.
Curcumin and Its Multi-Target Function Against Pain and Inflammation: An Update of Pre-Clinical Data. Uddin SJ, Hasan MF, Afroz M, et al. Current Drug Targets. 2021;22(6):656-671. doi:10.2174/1389450121666200925150022.
The Analgesic Effect of Curcumin and Nano-Curcumin in Clinical and Preclinical Studies: A Systematic Review and Meta-Analysis. Hajimirzaei P, Eyni H, Razmgir M, et al. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2025;398(1):393-416. doi:10.1007/s00210-024-03369-0.
Curcumin Inhibits Ferroptosis Through Dessuccinylation of SIRT5-associated ACSL4 Protein, and Plays a Chondroprotective Role in Osteoarthritis. Xu Y, Li Y, Liu L, Jing Q, Ye X. PloS One. 2025;20(8):e0328139. doi:10.1371/journal.pone.0328139.
Curcumin Exerts Chondroprotective Effects Against Osteoarthritis by Promoting AMPK/PINK1/Parkin-mediated Mitophagy. Jin Z, Chang B, Wei Y, et al. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2022;151:113092. doi:10.1016/j.biopha.2022.113092.
Curcumin Attenuates Environment-Derived Osteoarthritis by Sox9/NF-kB Signaling Axis. Buhrmann C, Brockmueller A, Mueller AL, Shayan P, Shakibaei M. International Journal of Molecular Sciences. 2021;22(14):7645. doi:10.3390/ijms22147645.
Evaluation of the Articular Cartilage in the Knees of Rats With Induced Arthritis Treated With Curcumin. Nicoliche T, Maldonado DC, Faber J, Silva MCPD. PloS One. 2020;15(3):e0230228. doi:10.1371/journal.pone.0230228.
The Mechanism of Curcumin Protecting Against IL-1β-induced Oxidative Stress and Inflammation in Chondrocytes via the Bmp2/Smad5/Runx2 Pathway. Li J, Liu W, Wang T, et al. Cytotechnology. 2025;77(2):71. doi:10.1007/s10616-025-00731-9.
The Efficacy of Curcumin in Relieving Osteoarthritis: A Meta-Analysis of Meta-Analyses. Bideshki MV, Jourabchi-Ghadim N, Radkhah N, et al. Phytotherapy Research : PTR. 2024;38(6):2875-2891. doi:10.1002/ptr.8153.
Curcumin for the Clinical Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials. Fan Y, Yi Z, Mao S, et al. Frontiers in Immunology. 2025;16:1726157. doi:10.3389/fimmu.2025.1726157.
Effect of Curcumin on Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Kou H, Huang L, Jin M, et al. Frontiers in Immunology. 2023;14:1121655. doi:10.3389/fimmu.2023.1121655.
Mechanistic Insight Into the Effects of Curcumin on Neuroinflammation-Driven Chronic Pain. Hasriadi, Dasuni Wasana PW, Vajragupta O, Rojsitthisak P, Towiwat P. Pharmaceuticals (Basel, Switzerland). 2021;14(8):777. doi:10.3390/ph14080777.
The Protective Role of Curcumin in Osteoarthritis: Establishing Mitochondrial Homeostasis Through Autophagy Induction and Apoptosis Inhibition. Raja K, Patnaik R, Suresh D, et al. International Journal of Molecular Sciences. 2026;27(2):609. doi:10.3390/ijms27020609.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.